Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.81 | N/A | +7.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.81 | N/A | +7.50% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation. They highlighted the importance of their pipeline in driving future growth.
Management highlighted strong performance in key therapeutic areas.
They expressed confidence in ongoing product development.
The focus remains on maintaining operational efficiency.
Pfizer's earnings report shows a positive surprise in EPS, which likely contributed to the stock's increase of 3.47%. The company did not provide revenue figures or guidance, but management's optimistic tone suggests confidence in their future prospects. Investors may view the EPS beat as a sign of underlying strength in Pfizer's operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KLA CORP
Jul 30, 2018